New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Bile Duct Cancer Market to Upsurge at a Significant CAGR by 2032, Assesses DelveInsight
The bile duct cancer market is anticipated to surge in the coming years due to the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate.
DelveInsight’s Bile Duct Cancer Market Insights report includes a comprehensive understanding of current treatment practices, bile duct cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Bile Duct Cancer Market Report
- As per DelveInsight analysis, the bile duct cancer market is expected to grow positively at a significant CAGR during the study period (2019–2032).
- According to the assessment done by DelveInsight, the estimated total bile duct cancer diagnosed incident cases in the 7MM were approximately 46K in 2021.
- Leading bile duct cancer companies such as Merck, AstraZeneca, Zymeworks, BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica, Celgene, Bristol Myer Squibb, Servier, and others are developing novel bile duct cancer drugs that can be available in the bile duct cancer market in the coming years.
- The promising bile duct cancer therapies in the pipeline include KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), FUTIBATINIB (TAS-120), TASURGRATINIB (E7090), TT-00420, LENVIMA (lenvatinib), ZANIDATAMAB, Nab-paclitaxel, LONSURF (Trifluridine and Tipiracil Hydrochloride/TAS-102), and others.
- The bile duct cancer market size may flourish due to increased research and development activities and the active participation of key players.
Discover which therapies are expected to grab the major bile duct cancer market share @ Bile Duct Cancer Market Report
Bile Duct Cancer Overview
Bile duct cancer (BDC), also known as Cholangiocarcinoma (CCA), is a cancer that develops in the slender tubes (bile ducts) that transport the digestive fluid bile. The bile ducts connect the liver to the gallbladder and the small intestine. Bile duct tumors can develop anywhere in the biliary tract and can be difficult to diagnose based solely on histopathologic examination. Bile duct cancer is classified anatomically into intrahepatic and extrahepatic bile duct cancer. Early studies on the genetic pathophysiology of bile duct cancers focused on determining the carcinogenic function of specific genes, which were frequently found to be mutated or altered by copy number changes in other cancers.
Endoscopic retrograde cholangiopancreatography and procedures such as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, and narrow-band imaging are typically used to make a definitive bile duct cancer diagnosis. The stricture’s neoplastic nature cannot be definitively demonstrated by MRI, CT, endoscopic ultrasonography, or 18FDG PET-CT.
Bile Duct Cancer Epidemiology Segmentation
DelveInsight estimates that there were approximately 46K diagnosed incident cases of bile duct cancer in the 7MM in 2021.
The bile duct cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Diagnosed-incidence Cases
- Total Type-specific Cases
- Total Age-specific Cases
- Total Stage-specific Cases
- Total Mutation-specific Cases
- Total Treated Cases (across lines)
Download the report to understand which factors are driving bile duct cancer epidemiology trends @ Bile Duct Cancer Epidemiological Insights
Bile Duct Cancer Treatment Market
Surgery with complete resection is the only curative bile duct cancer treatment option. Other bile duct cancer treatment options may include liver transplantation, which has been linked to rapid tumor recurrence and poor survival and is not currently recommended as a treatment for unresectable bile duct cancer. Systemic chemotherapy remains the mainstay palliative bile duct cancer treatment modality for patients with unresectable or metastatic bile duct cancer, and the role of adjuvant chemotherapy in bile duct cancer is not well defined. Still, chemotherapy has been recommended for patients with local recurrence after resection of pBDC.
Patients with unresectable BTC may benefit from photodynamic therapy. The role of radiation therapy in BTC is still unclear, but it has been recommended in margin-positive and node-positive iCCA and pCCA, and unresectable pCCA is ineligible for liver transplantation. Although it is debatable, various guidelines recommend that routine biliary drainage be avoided prior to staging and assessing resectability of bile duct cancer, as well as preoperatively.
To know more about bile duct cancer treatment, visit @ Bile Duct Cancer Treatment Drugs
Bile Duct Cancer Pipeline Therapies and Key Companies
- KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
- IMFINZI (durvalumab): AstraZeneca
- FUTIBATINIB (TAS-120): Taiho Oncology
- TASURGRATINIB (E7090): Eisai
- TT-00420: TransThera Sciences (Nanjing)
- LENVIMA (lenvatinib): Eisai and Merck & Co
- ZANIDATAMAB: Zymeworks and BeiGene
- Nab-paclitaxel: Celgene/Bristol Myer Squibb
- LONSURF (Trifluridine and Tipiracil Hydrochloride/TAS-102): Taiho Pharmaceutical/Servier
Learn more about the FDA-approved drugs for bile duct cancer @ Drugs for Bile Duct Cancer Treatment
Bile Duct Cancer Market Dynamics
The dynamics of the bile duct cancer market are expected to change in the coming years as a result of advances in diagnosis and a better understanding of the role of genetic aberrations, particularly in regions encoding key components of signaling pathways, allowing researchers to approach bile duct cancer from new angles and make discoveries. Moreover, when most patients are diagnosed, their illness is advanced or incurable, leaving systemic therapy as their only option for bile duct cancer treatment. It is well understood that tumor biology and clinical presentation, as do their etiological sources, differ between subgroups. When individuals with resectable illness first arrive, surgery may be curative, though these patients constitute a small percentage with high recurrence rates. Additionally, the recurrence patterns often prohibit additional curative resection.
Furthermore, many potential therapies are being investigated for the treatment of bile duct cancer in the pipeline, and it is safe to predict that the treatment space will significantly impact the market during the forecast period. The anticipated introduction of new therapies with improved efficacy, increased awareness initiatives, and further improvement in the diagnosis rate are all expected to drive the growth of the bile duct cancer market in the 7MM. Aside from that, the bile duct cancer may market grow due to increased research and development activities.
However, bile duct cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists in the coming years.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Bile Duct Cancer Companies | Merck, AstraZeneca, Zymeworks, BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica, Celgene, Bristol Myer Squibb, Servier, and others |
| Key Pipeline Bile Duct Cancer Therapies | KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), FUTIBATINIB (TAS-120), TASURGRATINIB (E7090), TT-00420, LENVIMA (lenvatinib), ZANIDATAMAB, Nab-paclitaxel, LONSURF (Trifluridine and Tipiracil Hydrochloride/TAS-102), and others |
Scope of the Bile Duct Cancer Market Report
- Therapeutic Assessment: Bile Duct Cancer current marketed and emerging therapies
- Bile Duct Cancer Market Dynamics: Attribute Analysis of Emerging Bile Duct Cancer drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Bile Duct Cancer Market Access and Reimbursement
Discover more about bile duct cancer drugs in development @ Bile Duct Cancer Clinical Trials
Table of Contents
| 1. | Bile Duct Cancer Market Key Insights |
| 2. | Bile Duct Cancer Market Report Introduction |
| 3. | Bile Duct Cancer Market Overview at a Glance |
| 4. | Bile Duct Cancer Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Bile Duct Cancer Treatment and Management |
| 7. | Bile Duct Cancer Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Bile Duct Cancer Marketed Drugs |
| 10. | Bile Duct Cancer Emerging Drugs |
| 11. | Seven Major Bile Duct Cancer Market Analysis |
| 12. | Bile Duct Cancer Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Bile Duct Cancer Market Drivers |
| 16. | Bile Duct Cancer Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Related Reports
Bile Duct Cancer Epidemiology Forecast
Bile Duct Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted bile duct cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Bile Duct Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bile duct cancer companies, including Midatech Pharma, Y-mAbs Therapeutics, ZIOPHARM Oncology, among others.
Biliary Tract Cancers Pipeline
Biliary Tract Cancers Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key biliary tract cancer companies, including Merck, RemeGen, EMD Serono, SMT bio Co., Ltd., among others.
Intrahepatic Cholangiocarcinoma Market
Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key intrahepatic cholangiocarcinoma companies, including Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, among others.
Intrahepatic Cholangiocarcinoma Pipeline
Intrahepatic Cholangiocarcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key intrahepatic cholangiocarcinoma companies, including Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, among others.
Intrahepatic Cholangiocarcinoma Epidemiology Forecast
Intrahepatic Cholangiocarcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted intrahepatic cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Bile Duct Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Blogs
Upcoming Oncological Drugs in 2023
Metastatic Castration-Sensitive Prostate Cancer Treatment Market
Checkpoint Inhibitor Refractory Cancer Market
Promising Oncolytic Virues Candidates in Pipeline
ENHERTU’s Journey in Cancer Treatment and Management
Potential of PD-1 and PD-L1 Inhibitors in Cancer Management
Evolving EGFR NSCLC Treatment Market Dynamics
Emerging Role of Digital Health in the Field of Oncology
Related Cases Studies
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
